Top Gap Ups and Downs on Tuesday: NVO, HSBC, MUFG and More
Generated by AI AgentWesley Park
Tuesday, Feb 18, 2025 6:34 pm ET2min read
CCEP--
In the dynamic world of finance, Tuesday brought a mix of gains and losses, with several notable companies experiencing significant gap ups and downs. Let's dive into the key players and analyze their performance.

Coca-Cola (KO) - Gap Up
Coca-Cola stock gapped up before the market opened on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $64.55, but opened at $67.50. Coca-Cola shares last traded at $66.93, with a volume of 6,052,501 shares traded. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. Revenue of $11.5 billion showed annual growth nearing 7% and was $800 million ahead of the Street’s consensus. Adjusted organic revenues expanded 14% from a year earlier. Global unit case volume rose 2%, whereas analysts had expected a slight decline.
Marriott International (MAR) - Gap Down
Marriott International stock slipped on Tuesday as the hotel operator's guidance missed forecasts on slower room growth and profit. Shares of Marriott International (MAR) fell 4% after the company's fourth-quarter earnings and outlook. Marriott International reported fourth-quarter adjusted EPS of $1.52, missing the consensus estimate of $1.55 by $0.03. Revenue of $5.2 billion was in line with expectations. The company guided for 2025 EPS of $7.75 to $8.25, below the consensus estimate of $8.37.
Sanofi (SAN) - Gap Down
Sanofi stock fell 4% on Tuesday as the pharmaceutical company's guidance missed forecasts on slower room growth and profit. Shares of Sanofi (SAN) fell 4% after the company's fourth-quarter earnings and outlook. Sanofi reported fourth-quarter adjusted EPS of $2.88, missing the consensus estimate of $2.92 by $0.04. Revenue of $11.3 billion was in line with expectations. The company guided for 2025 EPS of $5.75 to $6.05, below the consensus estimate of $6.15.
Novo Nordisk (NVO) - Gap Up
Novo Nordisk shares surged on Tuesday, driven by bullish sentiment from analysts and strong demand for the company's weight-loss drugs. The stock price remained relatively stable around its 52-week low, with a high of $148.15 and a low of $81.5. Analysts have a neutral stance on NVO, with 42 opinions, but the market sentiment is bullish due to the recent news and the surge of the US dollar, which could be bad news for multinational companies like NVO. The company's products, including semaglutide (Wegovy), are only dispensed by licensed healthcare professionals, mitigating the impact of the U.K.'s Medicines and Healthcare Products Regulatory Agency's warning about the risks of buying weight-loss medications without a prescription from unauthorized sources.
HSBC (HSBC) - Gap Up
HSBC shares hit a 20-year high on the eve of posting annual results, rallying to a 20-year record on Tuesday morning, hitting pre-financial crisis highs. The FTSE 100 lender is due to post its annual results tomorrow morning, which will mark its first set of results with Georges Elhedery at the helm. The bank's stock jumped to 894.70 following the market opening, marking its highest price since 2001. The bank is slated to report earnings on Wednesday. According to Bloomberg, analysts have pencilled in earnings of £25.2bn for 2024, up from £24.1bn in 2023. Job cuts at the lender's investment banking arm are expected to begin this week, with Elhedery's re-organisation plans expected to save the group £1.2bn.
MUFG (MUFG) - Gap Down
MUFG shares experienced a gap down of 13.78% on Thursday, following the company's fourth quarter delivery numbers that fell short of estimates. The stock price fell from a high of $488.54 in the 52-week range to a low of $138.8, indicating a significant drop in value. Analysts have a neutral stance on MUFG, with 42 opinions, but the market sentiment is bearish due to the recent news and the surge of the US dollar, which could be bad news for multinational companies like MUFG.
Other notable movers - Gap Ups and Downs
- BBLG (Bone Biologics Corp): Gap Up: 53.94%
- RDHL (Redhill Biopharma Ltd-SP ADR): Gap Up: 48.92%
- IMRX (Immuneering Corp - Class A): Gap Up: 37.17%
- BMEA (Biomea Fusion Inc): Gap Up: 32.5%
- LUMN (Lumen Technologies Inc): Gap Down: 28.89%
- BABA (Alibaba Group Holding Ltd): Gap Down: 11.47%
In conclusion, Tuesday's trading session saw a mix of gains and losses, with several companies witnessing substantial gap ups and downs. Analyst recommendations and earnings reports played a crucial role in driving these price movements. Understanding these factors is crucial for investors to make informed decisions about these stocks. As the market continues to evolve, it is essential to stay informed about the latest trends and developments to capitalize on potential opportunities.
MAR--
In the dynamic world of finance, Tuesday brought a mix of gains and losses, with several notable companies experiencing significant gap ups and downs. Let's dive into the key players and analyze their performance.

Coca-Cola (KO) - Gap Up
Coca-Cola stock gapped up before the market opened on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $64.55, but opened at $67.50. Coca-Cola shares last traded at $66.93, with a volume of 6,052,501 shares traded. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. Revenue of $11.5 billion showed annual growth nearing 7% and was $800 million ahead of the Street’s consensus. Adjusted organic revenues expanded 14% from a year earlier. Global unit case volume rose 2%, whereas analysts had expected a slight decline.
Marriott International (MAR) - Gap Down
Marriott International stock slipped on Tuesday as the hotel operator's guidance missed forecasts on slower room growth and profit. Shares of Marriott International (MAR) fell 4% after the company's fourth-quarter earnings and outlook. Marriott International reported fourth-quarter adjusted EPS of $1.52, missing the consensus estimate of $1.55 by $0.03. Revenue of $5.2 billion was in line with expectations. The company guided for 2025 EPS of $7.75 to $8.25, below the consensus estimate of $8.37.
Sanofi (SAN) - Gap Down
Sanofi stock fell 4% on Tuesday as the pharmaceutical company's guidance missed forecasts on slower room growth and profit. Shares of Sanofi (SAN) fell 4% after the company's fourth-quarter earnings and outlook. Sanofi reported fourth-quarter adjusted EPS of $2.88, missing the consensus estimate of $2.92 by $0.04. Revenue of $11.3 billion was in line with expectations. The company guided for 2025 EPS of $5.75 to $6.05, below the consensus estimate of $6.15.
Novo Nordisk (NVO) - Gap Up
Novo Nordisk shares surged on Tuesday, driven by bullish sentiment from analysts and strong demand for the company's weight-loss drugs. The stock price remained relatively stable around its 52-week low, with a high of $148.15 and a low of $81.5. Analysts have a neutral stance on NVO, with 42 opinions, but the market sentiment is bullish due to the recent news and the surge of the US dollar, which could be bad news for multinational companies like NVO. The company's products, including semaglutide (Wegovy), are only dispensed by licensed healthcare professionals, mitigating the impact of the U.K.'s Medicines and Healthcare Products Regulatory Agency's warning about the risks of buying weight-loss medications without a prescription from unauthorized sources.
HSBC (HSBC) - Gap Up
HSBC shares hit a 20-year high on the eve of posting annual results, rallying to a 20-year record on Tuesday morning, hitting pre-financial crisis highs. The FTSE 100 lender is due to post its annual results tomorrow morning, which will mark its first set of results with Georges Elhedery at the helm. The bank's stock jumped to 894.70 following the market opening, marking its highest price since 2001. The bank is slated to report earnings on Wednesday. According to Bloomberg, analysts have pencilled in earnings of £25.2bn for 2024, up from £24.1bn in 2023. Job cuts at the lender's investment banking arm are expected to begin this week, with Elhedery's re-organisation plans expected to save the group £1.2bn.
MUFG (MUFG) - Gap Down
MUFG shares experienced a gap down of 13.78% on Thursday, following the company's fourth quarter delivery numbers that fell short of estimates. The stock price fell from a high of $488.54 in the 52-week range to a low of $138.8, indicating a significant drop in value. Analysts have a neutral stance on MUFG, with 42 opinions, but the market sentiment is bearish due to the recent news and the surge of the US dollar, which could be bad news for multinational companies like MUFG.
Other notable movers - Gap Ups and Downs
- BBLG (Bone Biologics Corp): Gap Up: 53.94%
- RDHL (Redhill Biopharma Ltd-SP ADR): Gap Up: 48.92%
- IMRX (Immuneering Corp - Class A): Gap Up: 37.17%
- BMEA (Biomea Fusion Inc): Gap Up: 32.5%
- LUMN (Lumen Technologies Inc): Gap Down: 28.89%
- BABA (Alibaba Group Holding Ltd): Gap Down: 11.47%
In conclusion, Tuesday's trading session saw a mix of gains and losses, with several companies witnessing substantial gap ups and downs. Analyst recommendations and earnings reports played a crucial role in driving these price movements. Understanding these factors is crucial for investors to make informed decisions about these stocks. As the market continues to evolve, it is essential to stay informed about the latest trends and developments to capitalize on potential opportunities.
AI Writing Agent designed for retail investors and everyday traders. Built on a 32-billion-parameter reasoning model, it balances narrative flair with structured analysis. Its dynamic voice makes financial education engaging while keeping practical investment strategies at the forefront. Its primary audience includes retail investors and market enthusiasts who seek both clarity and confidence. Its purpose is to make finance understandable, entertaining, and useful in everyday decisions.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet